INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

Income Statement

Follow revenue through to earnings.

Revenue

$50,000.00

FY 2025 · Annual

+257.1% YoY

Operating Income

-$30.87M

FY 2025 · Annual

Net Income

-$45.93M

FY 2025 · Annual

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue181K374K155K14K50K
Cost of Revenue00000
Gross Profit181K374K155K14K50K
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development20.54M17.07M20.27M33.17M20.66M
Selling, General & Admin8.79M9.26M9.62M9.48M10.26M
Operating Expenses29.33M26.33M29.9M42.65M30.92M
Depreciation & Amortization29.15M25.95M29.74M553K84K
EBITDA(1.19M)(1.35M)(267K)(41.53M)(45.85M)
EBITDA Margin-655.8%-360.4%-172.3%-296635.7%-91698.0%
Operating Income(29.15M)(25.95M)(29.74M)(42.64M)(30.87M)
Operating Margin-16106.6%-6938.8%-19187.7%-304535.7%-61738.0%
Interest Income0000850K
Interest Expense00000
Other Income / Expenses(1.19M)(1.35M)(267K)553K(15.06M)
Income Before Tax(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Pre-Tax Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
Income Tax Expense00000
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Net Margin-16762.4%-7299.2%-19360.0%-300585.7%-91866.0%
EPS (Basic)(1.88)(1.52)(1.67)(2.11)(1.86)
EPS (Diluted)(1.88)(1.52)(1.67)(2.11)(1.86)
Weighted Avg Shares16.13M17.93M17.98M19.94M26.59M
Weighted Avg Shares (Diluted)16.13M17.93M17.98M19.94M26.59M

INMB Earnings Waterfall · TTM

NASDAQ:INMB · Revenue to Net Income

Key Ratios

EPS$-1.69
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.5
P/S Ratio0.0

Analysis

$0 of revenue converted into -$41.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.69, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
3Initial statement of beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 17, 2026
3Initial statement of beneficial ownershipSep 16, 2026
8-KCurrent reportSep 14, 2026

How much revenue does INMB generate?

INmune Bio, Inc. (INMB) reported $50,000.00 of revenue in fiscal 2025.

Is INMB profitable?

INmune Bio, Inc. (INMB) reported -$45.93M of net income, with a net margin of -91866.0%.